Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM): 8 pipeline candidates · ~28 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
27.7 months
D/E 0.27 · 1% dilution
Lead: Approved
8 candidates
N/A
0 buys · 20 sells (180d)
A transparent, data-derived signal for Beam Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.2B
Cash
$295.0M
Quarterly Burn
$128.5M
Runway
27.7 mo
Revenue
$31.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| BEAM-101 | Phase 1/Phase 2 |
| BEAM-103 | Phase 1/Phase 2 |
| BEAM-104 | Phase 1/Phase 2 |
| BEAM-301 | Phase 1/Phase 2 |
| BEAM-302 | Phase 1/Phase 2 |
| BEAM-304 | Phase 1/Phase 2 |
| Ristoglogene autogetemcel (risto-cel) | Phase 1/Phase 2 |
| sunlight omnisense 7000s | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
251
Total value held
$2.54B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 12,452,199 | $296.7M |
| ark investment management llc | 12,133,433 | $289.1M |
| farallon capital management llc | 10,134,696 | $241.5M |
| vanguard capital management llc | 8,754,748 | $208.6M |
| blackrock, inc. | 8,487,569 | $202.3M |
| state street corp | 5,699,265 | $135.8M |
| vanguard portfolio management llc | 4,570,797 | $108.9M |
| arch venture management, llc | 4,540,132 | $108.2M |
| amova asset management americas, inc. | 3,825,585 | $91.2M |
| kynam capital management, lp | 3,682,185 | $87.7M |
Showing top 10 of 251 institutional holders of Beam Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Beam Therapeutics Inc.'s pipeline?
Beam Therapeutics Inc. (BEAM) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Beam Therapeutics Inc.'s lead drug candidate?
Beam Therapeutics Inc.'s most advanced tracked candidate is BEAM-101 (Phase 1/Phase 2) for Sickle Cell Disease.
What is Beam Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Beam Therapeutics Inc. has approximately 27.7 months of cash runway.
What is Beam Therapeutics Inc.'s market capitalization?
Beam Therapeutics Inc.'s market capitalization is approximately $3.2B.
Who is the CEO of Beam Therapeutics Inc.?
Mr. John M. Evans M.B.A. is the chief executive officer of Beam Therapeutics Inc. (BEAM).
Get the full picture on Beam Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.